<img height="1" width="1" style="display:none" src="https://q.quora.com/_/ad/fddcdc9dc8954bf7bdefaa9d33414665/pixel?tag=ViewContent&amp;noscript=1">

Liquid biopsy platforms getting more attention (and more money)

March 18, 2021

Agilent Technologies (@agilent), a Santa Clara, Calif.-based analytical instrumentation development and manufacturing company, is acquiring Resolution Bioscience for $550 million in cash and up to an additional $145 million if certain milestones are met. Resolution Bioscience is a precision oncology company based in Kirkland, Wash., that has a next-generation sequencing-based noninvasive liquid biopsy test platform.

A March 2020 article in Nature describes a liquid biopsy this way: “the analysis of tumors using biomarkers circulating in fluids such as the blood.” Liquid biopsies can be used for the screening and early detection of cancer. They can also help determine a patient’s condition both after diagnosis and relapse. 

What did ResoluteAI learn about liquid biopsy platforms?


Tech transfers in this area


Liquid biopsy tech transfers from 2011 through 2020liquid biopsy tech transfers from 2011 through 2020

News on liquid biopsy platforms

Some of the organizations receiving grants on liquid biopsy platforms are:

Leading researchers in liquid biopsy are:


Research across all of these databases was conducted quickly and efficiently using ResoluteAI’s Foundation. To talk to a real person about how Foundation can help your company or organization, please email us at info@resolute.ai or drop us a line using the link below.

Let's talk


Lesley Pink

Lesley Pink, our senior digital editor/writer, has written across a range of industries including artificial intelligence, actuarial science, government, law, and financial journalism. She's a fan of the serial comma and mint chocolate chip ice cream. And no, pink is not her favorite color. You can reach Lesley at lesley@resolute.ai.